Royal Bank of Canada Has $16.45 Million Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Royal Bank of Canada decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.3% during the first quarter, HoldingsChannel reports. The firm owned 213,919 shares of the specialty pharmaceutical company’s stock after selling 7,379 shares during the quarter. Royal Bank of Canada’s holdings in ANI Pharmaceuticals were worth $16,451,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of ANIP. The Manufacturers Life Insurance Company boosted its holdings in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 143 shares during the period. Quantinno Capital Management LP raised its holdings in ANI Pharmaceuticals by 345.4% in the 1st quarter. Quantinno Capital Management LP now owns 15,167 shares of the specialty pharmaceutical company’s stock worth $1,166,000 after acquiring an additional 11,762 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in ANI Pharmaceuticals by 19.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after acquiring an additional 91,153 shares during the last quarter. Mizuho Markets Americas LLC lifted its position in ANI Pharmaceuticals by 4.3% during the 1st quarter. Mizuho Markets Americas LLC now owns 210,768 shares of the specialty pharmaceutical company’s stock worth $16,208,000 after acquiring an additional 8,774 shares during the last quarter. Finally, Sei Investments Co. lifted its position in ANI Pharmaceuticals by 36.8% during the 1st quarter. Sei Investments Co. now owns 57,168 shares of the specialty pharmaceutical company’s stock worth $4,395,000 after acquiring an additional 15,367 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Canaccord Genuity Group started coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 price objective for the company. Guggenheim reissued a “buy” rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $105.00.

Insider Activity

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 2,850 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the completion of the transaction, the chief financial officer directly owned 174,693 shares of the company’s stock, valued at approximately $14,213,022.48. The trade was a 1.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director owned 38,432 shares in the company, valued at $3,098,772.16. The trade was a 20.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 88,029 shares of company stock worth $6,954,472. 8.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Trading Up 3.4%

ANIP stock opened at $82.63 on Friday. The business has a fifty day moving average price of $81.03 and a 200 day moving average price of $79.38. ANI Pharmaceuticals, Inc. has a fifty-two week low of $67.98 and a fifty-two week high of $99.50. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 20.92 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the prior year, the business earned $1.70 earnings per share. The business’s revenue for the quarter was up 20.5% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.